For new medical technologies to be adopted in over-burdened systems like the NHS, proof of efficacy in a lab is insufficient. The 'real acid test' is demonstrating that the technology works on the front lines of a busy, complex hospital. This real-world evidence is essential for gaining buy-in from skeptical staff.

Being patient-centered is necessary but insufficient for adoption. Technology in healthcare must be seamlessly embedded into a physician's existing, time-constrained workflow. Great tech that adds friction will be ignored, regardless of its potential patient benefit.

For new technologies to gain adoption in pharma, the central value proposition must be about de-risking decisions. Leaders and regulators often view the technology as a "black box" and are less concerned with its mechanics than with its ability to give them confidence in making safer, more reliable choices.

Many therapies fail to meet real-world expectations because they are designed for the lab, not life. Innovations focus on clinical efficacy, which drives only 20% of health outcomes, while ignoring the 80% driven by crucial psychological, social, and environmental factors.

Unlike controlled clinical trial data, real-world evidence is derived from vast, messy, and incomplete data from daily healthcare. This variability is its strength, offering deeper insights into long-term outcomes, drug interactions, and diverse patient populations that clean trial data misses.

MedTech's data-driven culture fosters a false belief that strong clinical data is sufficient to drive adoption. In reality, all humans—including surgeons—make decisions emotionally first. Data's primary role is not to create initial belief but to provide rational validation for a change the market has already been primed to make.

To gain physician trust, AI companies must move beyond proving their algorithm is accurate. The gold standard is large-scale clinical evidence demonstrating tangible improvements in patient outcomes, treatment rates, and decision-making speed.

Many MedTech companies mistakenly believe a clinically superior product will automatically win market share. This is false. Market adoption is not automatic; it must be designed as intentionally as the product itself to overcome the powerful inertia of the status quo and make the market mentally ready for change.

Even after proving a device works, getting FDA clearance, and securing a reimbursement code, investors' final question is about market traction. They want to see revenue before funding the sales team required to generate it, creating a final catch-22.